Nipah virus outbreak in Kerala state, India amidst of COVID-19 pandemic

^{1*}Pragya D. Yadav, Ph.D, ¹Rima R. Sahay, M.D., ²Anukumar B, Ph.D, ¹Sreelekshmy Mohandas, Ph.D, ³Chandni Radhakrishnan, M.D., Ph.D., ¹Mangesh D Gokhale, Ph.D., ²R Balasubramaniam, Ph.D., ¹Priya Abraham, M.D., Ph.D., ⁴Nivedita Gupta, Ph.D., ²AP Sugunan, MAE., ⁵Rajan Khobragade, M.B.B.S, ³Kalpana George, M.D., ¹Anita Shete, Ph.D., ¹Savita Patil, MSc., ¹Ullas Padinjaremmattathil Thankappan, Ph.D., ¹Hitesh Dighe, MSc., ²Jijo Koshy, B.A., ²Vivek Vijay, M.Sc., ³Gayathri R, M.D., ³P Jayesh Kumar M.D., ³Asma Rahim M.D., ⁶Naveen A., MBBS, ⁷Sarala Nair., M.B.B.S, ³VR Rajendran, M.D., ⁸Jayasree V, M.B.B.S., ¹Triparna Majumdar, MSc., ¹Rajlaxmi Jain, Ph.D., MSc., ³Prasanth Vishwanathan, Ph.D., ¹Deepak Y. Patil, Ph.D., ¹Abhinendra Kumar, Ph.D., ¹Dimpal A. Nyayanit, Ph.D., ¹Prasad Sarkale, M.Sc., ¹Ashwini Waghmare, B.Sc., ¹Shrikant Baradkar, M.Sc., ¹Pranita Gawande, M.Sc., ¹Poonam Bodake, M.Sc., ¹Kaumudi Kalele, M.Sc., ¹Jyoti Yemul, M.Sc., ¹Sachin Dhaigude, SSC., ¹Manjunath Holepannawar, SSC., ¹Sanjay Gopale, HSC., ¹Ganesh Chopade, SSC., ⁴Jitendra Narayan PhD., ¹Basavaraj Mathapati, Ph.D., ¹Manoj Kadam, B.Sc., ¹Abhimanyu Kumar, B.Sc., ¹Annasaheb Suryawanshi, B.Sc., ³Beena Philomina Jose, M.D., ³Saritha Sivadas, M.Sc., ³Akash NP, M.Sc., ³Vimisha TV, M.Sc., ³Keerthi KV, B.Sc.

¹Indian Council of Medical Research-National Institute of Virology, Pune, India

²Indian Council of Medical Research-National Institute of Virology, Kerala Unit, Alappuzha, India

³Government Medical College, Kozhikode, Kerala, India

⁴Indian Council of Medical Research, New Delhi, India

23 ⁵Health and Family Welfare Department, Government of Kerala, India

24 ⁶National Health Mission, Kozhikode, Kerala, India

25 ⁷District Surveillance Officer, Kozhikode, Kerala, India

26 ⁸District Medical Office of Health, Kozhikode, Kerala, India

27 * **Correspondence:**

28 Dr Pragya Yadav, Scientist E & Head, Maximum Containment Facility, ICMR-National Institute of

29 Virology, Pune, Maharashtra, India, email: hellopragya22@gmail.com

30 Abstract

31 **Background:** We report here a Nipah virus (NiV) outbreak in Kozhikode district of Kerala state,
32 India which had caused fatal encephalitis in an adolescent male and the outbreak response which led
33 to the successful containment of the disease and the related investigations.

34 **Methods:** Quantitative real-time RT-PCR, ELISA based antibody detection and whole genome
35 sequencing were performed to confirm the Nipah virus infection. Contacts of the index case were
36 traced and isolated based on risk categorization. Bats from the areas near the epicenter of the
37 outbreak were sampled for throat swabs, rectal swabs and blood samples for Nipah virus screening
38 by real time RT-PCR and anti-Nipah virus bat IgG ELISA. Plaque reduction neutralization test was
39 performed for the detection of neutralizing antibodies.

40 **Results:** Nipah viral RNA and anti-NiV IgG antibodies were detected in the serum of the index case.
41 Rapid establishment of an onsite NiV diagnostic facility and contact tracing helped in quick
42 containment of the outbreak. NiV sequences retrieved from the clinical specimen of the index case
43 formed a sub-cluster with the earlier reported Nipah I genotype sequences from India with more than
44 95% similarity. Anti-NiV IgG positivity could be detected in 21% of *Pteropus medius* and 37.73% of
45 *Rousettus leschenaultia*. Neutralizing antibodies against NiV could be detected in *P.medius*.

46 **Conclusions:** Stringent surveillance and awareness campaigns needs to be implemented in the area
47 to reduce human-bat interactions and minimize spill over events which can lead to sporadic outbreaks
48 of NiV.

49 **Keywords:** Nipah virus, outbreak, Kerala, *Pteropus medius*, bats, seropositivity

50

51

52 Introduction

53 Nipah virus (NiV) causes a highly lethal disease with acute severe encephalitis and acute respiratory
54 distress syndrome in humans. NiV is a *Paramyxovirus* that was identified for the first time during an
55 outbreak of severe encephalitis among the pig-farmers in Malaysia during 1998¹. The virus is
56 transmitted to humans by direct contact with the respiratory secretions or body fluids of infected
57 animals such as bats and pigs or by consumption of contaminated fruits/palm sap. Both animal-to-
58 human and human-to-human transmission have been documented ².

59 The disease has been enlisted as a priority disease in the Research and Development blueprint of the
60 World Health Organization (WHO) from the year 2015. South-East Asia is considered as an endemic
61 region for the virus². In Malaysia and Singapore outbreak, humans acquired the infection through the
62 contact with infected pigs^{1,3}. Subsequently, an outbreak with encephalitis among human population
63 was observed in Meherpur, Bangladesh during 2001 where the source of infection was traced down
64 to drinking the contaminated raw palm sap or climbing the trees coated with bat excrement⁴. India
65 has witnessed two outbreaks of Nipah virus encephalitis in the eastern state of West Bengal,
66 bordering Bangladesh^{5,6}. The first outbreak of NiV was observed among hospital visitors and health
67 workers after coming in contact with a hospitalized patient in Siliguri during January and February
68 2001⁵. In the year 2007, a second NiV outbreak was reported from Nadia district of West Bengal⁶. A
69 case fatality of 70-100% was observed during these two outbreaks^{5,6}. Since 2010, Indian Council of
70 Medical Research-National Institute of Virology (ICMR-NIV), Pune has taken up the surveillance of
71 NiV in bat populations across the country. During this, the presence of NiV was detected among
72 *Pteropus medius* from Myanaguri, West Bengal in 2010 and Cooch Bihar district, West Bengal and
73 Dhubri district, Assam in 2015^{7,8}.

After a decade of the last outbreak, a dreadful emergence of NiV was observed in Kozhikode district, Kerala State during May 2018 with case fatality rate of 89%⁹. The outbreak was contained with the quick actions of national and state health system¹⁰. A year later, a young male from Ernakulam district, Kerala got infected with NiV. Due to the early detection; the further spread of the virus was quickly curtailed. A detailed outbreak investigation to find the source of NiV infection was carried out by ICMR-NIV, Pune during these outbreaks which showed the presence of NiV and anti-NiV antibodies in *Pteropus medius*¹¹. The unprecedented emergence of NiV in the Kerala state in 2018 and 2019 raised a serious concern. Recently a NiV outbreak was reported in Kozhikode Kerala in September 2021, where an adolescent male who presented with acute encephalitis and tested positive for NiV, succumbed to the infection.

Here, we describe the 2021 NiV outbreak management in Kozhikode district, Kerala, India with emphasis on the field laboratory set up and quick diagnosis along with the bat survey to trace the source of infection. Immediately after confirming the NiV infection in September 2021, outbreak containment response was initiated in the state of Kerala.

Materials and Methods

Case history

In August 2021, an adolescent male (index case) resident of Kozhikode district, Kerala state, India developed low grade fever (Supplementary Figure.1). His family took him to a nearby private clinic (Hospital-1) and sought treatment for fever. In August 2021 his condition deteriorated and he was transferred to another hospital (Hospital-2). In September 2021, the patient's condition deteriorated further and he developed symptoms of acute encephalitis and myocarditis. On the request of his family, he was transferred to a tertiary care hospital in Kozhikode (Hospital-3). Magnetic resonance imaging of the brain showed multiple small infarcts in the cerebellum, cerebrum, medulla oblongata

and pons. With a high suspicion of NiV infection, his clinical samples including plasma, EDTA blood, serum, and cerebrospinal fluid (CSF) samples, endotracheal (ET) secretion and bronchial wash were sent to ICMR- NIV in September 2021.

Bat trapping and sample collection

For understanding the source of NiV infection and considering a brief history given by parent of the index case regarding the consumption of fruit from the orchard near the house, bat sampling was done during the month of September 2021. The sampling was performed with the prior approval from the Institutional Animal Ethics Committee, Institutional Biosafety Committee of ICMR-NIV, Pune and the Principal Chief Conservator of Forests, Government of Kerala. Four roosting sites were chosen from nearby vicinity of the index case house for sample collection (Supplementary Figure.1). These sites were in Kodyathur, Cheruvadi, Omassery and Thamarassery) in the state of Kerala, India. Bats were trapped using the mist nets as described earlier¹¹. Body weight, sex, secondary sexual characters and forearm length were noted. Blood (n=91), throat (n=102) and rectal swab (n=102) samples were collected from the trapped bats following isoflurane anesthesia. Species identification was performed by mitochondrial Cytochrome b gene PCR as described earlier.¹²

Real time quantitative RT-PCR

Real-time reverse transcriptase polymerase chain reaction (qRT-PCR) was performed on the samples for the NiV diagnosis as described earlier¹³. One ml of serum/swab samples were used for RNA extraction in an extraction machine using Magmax Viral RNA isolation kit as per manufacturer's instructions. Five microlitre extracted RNA was used for qRT-PCR using primers designed for Nipah NP gene.¹³ For SARS-CoV-2 detection, qRT-PCR was performed for throat/nasal swab samples using primers for E gene as described earlier¹⁴.

119 **Anti-Nipah human IgM ELISA**

120 The assay was performed as described earlier¹¹. Briefly, the microtiter plates were coated with 1: 100
 121 diluted anti-human IgM antibodies (Sigma, USA) overnight at 4°C. Following blocking of the wells
 122 with 2% bovine serum albumin for 2 hours at room temperature, 100 µl of 1:100 diluted heat
 123 inactivated serum samples were added to duplicate wells and was incubated at 37°C for one hour.
 124 After washing with wash buffer for four times, inactivated NiV antigen (positive antigen) and Vero-
 125 CCL81 cell lysate (negative antigen) were added and incubated for one hr at 37°C. The plates were
 126 washed and anti-NiV biotinylated antibodies were added and incubated for one hour. This was
 127 followed by washing and addition of Streptavidine Horseradish peroxidase (HRP) and incubation for
 128 30 min at 37°C. As substrate, one hundred µl of 3, 3',5,5'-Tetramethylbenzidine (TMB) was added
 129 and incubated for 10 minutes. The reaction was stopped by 1 N sulphuric acid, and the absorbance
 130 was measured at 450 nm. The assay cut off were an Optical Density (OD) value more than or equal
 131 to 0.20 and the positive/negative (P/N) ratio more than or equal to 1.5.

132 **Anti-Nipah human IgG ELISA**

133 Briefly, microtiter plates were coated with 0.1 ml of inactivated NiV antigen and normal Vero
 134 CCL81 cell lysate as negative antigen in carbonate buffer (pH 9.2, 0.025 M) overnight at 4°C. The
 135 wells were blocked with liquid plate sealer (Candor, USA) for 2 hours at room temperature. The
 136 plates were washed five times using 10 mM PBS (pH 7.4) with 0.1% Tween-20 (Sigma, USA) at the
 137 end of each step. Hundred micro litre of 1:100 diluted heat inactivated human serum samples were
 138 added to both positive and negative antigen wells and was incubated at 37°C for one hour. After
 139 washing, 100 micro litre of 1:15000 dilution of anti-human IgG HRP antibodies were added and
 140 incubated for one hr at 37°C. After washing, 100 µl of TMB substrate was added and incubated for
 141 10 minutes. The reaction was stopped by 1 N sulphuric acid and plates were read at 450 nm. OD

value more than or equal to 0.35 and the P/N ratio more than or equal to 1.5 was considered as positive.

Whole Genome Sequencing (WGS)

To identify the NiV genotype, WGS was carried out on different clinical samples obtained from the patient. RNA was extracted from the clinical samples and WGS was performed using the methods described earlier¹⁵. The viral reads generated were analyzed using reference-based mapping, performed in CLC Genomics Workbench version 21.0.4. In order to retrieve the complete genome sequence of the virus all the generated reads were mapped to the reference genome. Phylogenetic analyses and the amino acid variations of the retrieved NiV sequence with the other representative NiV sequences of earlier outbreaks were performed. SARS-CoV-2 positive samples were sequenced as per the method described earlier to identify the lineage in circulation¹⁶.

Anti-NiV bat IgG ELISA

The assay was performed as described earlier¹⁵. NiV antigen/uninfected Vero CCL81 cell lysate antigen coated microtiter plates were used. Diluted bat sera samples were added and incubated for one hour in the microtiter plates at 37°C. The plates were washed four times following the incubation period using wash buffer. Hundred microliter of anti-bat IgG HRP conjugate (1:2000 dilution) was added and incubated. TMB substrate (Clinical Science Product incorporation NeA blue, USA) was added after washing and was again incubated at 37°C for 15 minutes. The reaction was stopped and plates were read at 450 nm.

Plaque reduction neutralization test

Heat inactivated bat serum samples were mixed with NiV (GenBank accession number: MH523642) containing 50 plaque forming units in 1:1 ratio so as to make a final 10-fold dilution of the serum virus mixture. Anti-Nipah IgG positive mice serum was used as positive control and Anti-Nipah IgG negative mice serum was used as negative control. The mixture was incubated for 1 hour and was added to 24-well tissue culture plate containing a confluent monolayer of Vero CCL-81 cells. The plate was incubated in a CO₂ incubator at 37°C for one hour and an overlay medium containing 2% Carboxy methyl cellulose in 2X Minimal Essential Media with 2% fetal bovine serum was added after removing the inoculum. The plate was further incubated at 37°C in CO₂ incubator for 3 days. After removing the overlay medium, the plate was washed and stained with amido black. The plaques were counted. The titre was defined as the highest serum dilution that resulted in 50 per cent (PRNT₅₀) reduction in the number of plaques.

Results

Detection and confirmation of NiV infection

NiV infection was confirmed by qRT-PCR and by the detection of anti-Nipah IgM antibodies in serum sample of the patient. Virus isolation attempts from the samples in Vero CCL-81 cells were not successful. In September 2021, NiV outbreak in Kerala was declared by the Ministry of Health and Family Welfare, Government of India. The patient succumbed to the infection in September 2021. Contact tracing and isolation of high-risk contacts, augmentation of laboratory testing capacity, bat sampling and laboratory investigations were undertaken following the event as described below.

Establishment of an on-site field NiV diagnostic facility

A team from ICMR-NIV Pune had set up a field diagnostic laboratory in the Department of Microbiology, Government Medical College, Kozhikode, Kerala by September 2021 following all the essential biosafety guidelines and standard operating procedures. The field laboratory screened a total of 125 NiV suspected asymptomatic contacts as well as non-epidemiologically linked suspected NiV cases by qRT-PCR.¹⁰

Risk categorization and contact tracing:

After declaration of NiV outbreak, systematic field investigations were undertaken to identify the epidemiologically linked close contacts, including health care workers, family members, neighbours, bystanders, etc. The close contacts were classified into primary contacts and secondary contacts and were further grouped into high-risk and low-risk contacts. The high-risk category included individuals with either a history of direct contact with body fluids (blood, urine, saliva, vomitus, etc.) of the confirmed NiV case/a probable case that died without laboratory confirmation or having spent about 12 hour nearby or in closed space with confirmed NiV case. The low-risk contacts were categorized as those having contact with the confirmed NiV case through touching or contact with clothes, linen, or any other items. Samples of symptomatic contacts were shipped to the Biosafety Level 4 (BSL-4) laboratory of ICMR-NIV, Pune for diagnosis. All asymptomatic contacts were tested on site at the field laboratory. Considering the ongoing COVID-19 pandemic, all the close contacts were also screened for SARS-CoV-2.

A total of 240 contacts were listed and among them 64 close contacts [33 female/31 male] were identified and grouped into primary high-risk (n=50) and low-risk (n=9) contacts; secondary high-risk (n=3) and low-risk (n=2) contacts (Figure. 1). Out of 59 primary contacts, 40 were asymptomatic while all the 5 secondary contacts were asymptomatic (Supplementary Table.1). All the 64 close contacts tested negative for NiV by qRT-PCR and anti-NiV IgM and IgG ELISA.

The throat/nasal swab of the 12 close contacts (symptomatic-8 and asymptomatic-4) were found positive for SARS-CoV-2 by qRT-PCR (Supplementary Table.1). On sequencing of SARS-CoV-2 positive samples (n=12), Delta variant (B.1.167.2) and its derivatives (AY.26) were detected in ten and two cases respectively.

Genomic characterization of NiV from clinical specimens of the index case

A phylogenetic analysis was performed for the retrieved NiV sequence (17066 nucleotide) with the other representative NiV sequences of the earlier outbreaks (Figure.2, Supplementary table 2). The retrieved sequence clearly segregated from the Bangladesh NiV sequences and clustered into earlier described Indian ('I') genotype. The retrieved sequence showed 99.62 and 99.51 percent nucleotide similarity (PNS) with sequences obtained from human samples during 2018 NiV outbreak and *P. medius* samples during 2019 outbreak respectively. A detailed PNS of the representative NiV sequences with that of the NiV sequence from Malaysia (Accession Number: NC_002728.1) is provided in the Table.1.

The different genes of NiV showed amino acid variation between the Bangladesh and I genotype cluster. The changes observed were in the N gene (S503N, P520S, E752G, Q758E, R818H, I820L, T919N, Q982R, A1162T, and G1216D), F gene (I15L) and G gene (R344M, I384V, V427I) of I genotype of the NiV compared to the NC_002728.1. Similarly, the changes were observed in the N gene (R505K, S900G, D921N), G gene (R344K, K386E, T498K) and L gene (R1262K, N 237D) when the Bangladesh (BD) NiV sequences were compared to the NC_002728.1 (Table.2).

Detection of anti-NiV IgG antibodies in bat samples

The bat species sampled in the study included *Pteropus medius* (n=38), *Rousettus leschenaultia* (n=63) and *Pipistrellus sp.* (n=1) (Supplementary Table.3). All the bat samples were found to be negative for Nipah viral RNA (Table.3). The serum samples of *P. medius* (n=8) and *R. leschenaultia*

($n=20$) were tested positive for anti-NiV IgG antibodies. The *P. medius* samples from two sites ie., Kodyathur and Thamarassery showed positivity of 20% and 56% by ELISA respectively and was further confirmed by PRNT. Two samples were excluded from the assay due to insufficient sample quantity. *R. leschenaulti* samples which showed seropositivity by ELISA were found negative for neutralizing antibodies (Table.3).

Discussion

Nipah virus outbreaks have been reported from Malaysia, Singapore, Bangladesh and India with a range of clinical presentations and case fatality rate of 40 to 100%.¹⁻⁷ Malaysia and Singapore had reported single NiV outbreak episode whereas Bangladesh reports annual outbreaks of NiV⁴. In India NiV outbreaks have been localized to two regions ie., in the North eastern region of West Bengal and in the southernmost region of Kerala which are separated by a distance of more than 2000 km.^{5,6,9-11} NiV outbreaks are mostly sporadic and the magnitude of the outbreak can be restricted by prompt public health response and containment measures. In 2018, the first NiV outbreak was reported in Kerala state with significant number of losses of lives (91% fatality) and in the year 2019 and 2021 outbreaks in Kerala reported only single case without any further human to human transmission.^{9,11} The diagnosis of the NiV infection is difficult considering the overlapping presentations of the acute respiratory infections and encephalitis syndromes. In the current SARS-CoV-2 pandemic scenario, the diagnosis became even more challenging considering the overlapping clinical features. The quick outbreak containment response and the biosafety practices followed during the COVID-19 pandemic period in Kerala state might have helped in preventing further transmission and restricting the outbreak to a single case.

The role of intermediate hosts like pigs and bats has been demonstrated in the NiV transmission cycle in the previous reported outbreaks.^{1,3,4} *Pteropus* genus of bats appears to be the major reservoir of the

254 NiV.^{8,18,20} *P. medius* is the only *Pteropus* genus bat present in the Indian subcontinent.¹⁹ *Pteropus*
 255 bats has shown NiV RNA positivity or seropositivity from Indian states like West Bengal, Assam,
 256 Haryana and Kerala indicating the risk of spill-over.^{7,8,11,20} Viral genome recovered from the current
 257 outbreak also clustered with the previously reported NiV genotype from Kerala in bats and humans
 258 samples. This suggests a stable genotype circulating locally in bat population in Kerala. Research has
 259 shown NiV evolves at a slower rate compared to other similar RNA viruses.^{21,22} In 2018, the
 260 outbreak occurred in Perambra, Kozhikode which is about 40 km far from the location of the present
 261 outbreak.⁹ A total of 23 cases and 21 deaths were reported. 21% of the *Pteropus medius* bats
 262 surveyed in the vicinity of the index case residence. In 2019, NiV RNA positivity was documented in
 263 *P. medius* bats from Thodupuzha which is more than 200 km from Kozhikode district.¹¹ *Pteropus*
 264 species movement could also play an important role in virus spread, but in India such records are not
 265 available. Home ranges of *P. medius* appear to be smaller than *P. vampyrus*, another frugivorous bat
 266 in Malaysia and this depend on food availability¹⁸. Studies on the *Pteropus* species movement and
 267 connectivity among the bat populations could help us in understanding the potential of virus spread
 268 to bat colonies of adjacent areas.

269 NiV RNA could not be detected in any of the bats samples in the present study. Previous studies have
 270 also reported a low PCR positivity in *P. medius*.^{18,23,24} Virus shedding in bats is driven by multiple
 271 factors like individual immune status, pregnancy, virus recrudescence, stress etc.^{18,24} Re-infection in
 272 adult bats are possible in approximately 7 years²⁴. We detected 25% and 3.2% NiV positivity in bats
 273 from outbreak regions of Kerala in 2018 and 2019.^{9,11} High seroprevalence in the bat colonies can
 274 dampen the virus transmission.¹⁸ Seasonality of NiV outbreaks have been reported is linked to the
 275 breeding season and fruit harvesting season.²⁵ Unlike the previous reported outbreaks in the month of
 276 May and June in Kerala, the present outbreak was in August end. A cross sectional spatial study

277 conducted between 2006 and 2012 in Bangladesh reports the ability of NiV shedding by *P. medius*
278 throughout the year.¹⁸

279 During the current outbreak investigations, we could detect antibodies in a total of 21% *P. medius*
280 bats. If we further classify this positivity, site wise, a 20% positivity was observed in Kodyathur, a
281 site within 1 km distance from the index case house and 55.6% in Thamarassery, a site 18 km far
282 from this outbreak. During the investigation, 2 juvenile *P. medius* bats were found positive for anti-
283 NiV IgG antibodies. The seroprevalence in the juveniles is an indicator of enzootic cycle of NiV in
284 recent past. Waning of immunity with time and loss of maternal antibodies could affect the
285 transmission dynamics within the bat colonies.^{18,24} Local NiV epizootics in bats contribute to the
286 outbreaks in Bangladesh.¹⁸ Sporadic natures of outbreaks in case of NiV are explained by the NiV
287 dynamics in the resident bat colonies and the bat-human interface resulting in spill over.

288 Non-pteropid bats have shown NiV seropositivity in many countries.^{17,23,26,27} In India, other than *P*
289 *medius*, bats like *R. leschenaultia* and *P. pipistrellus* have shown seropositivity by ELISA.¹⁷
290 Interspecies transmission could be possible with other frugivorous bats as they share same habitat for
291 food resources. Similarly, in the present study, we could detect seropositivity in *R. leschenaultia* bats
292 by ELISA. But absence of NAb against NiV in these bats points to the possibility of detection of
293 related Henipaviruses in these bats. Similar observations are reported in Vietnam where the ELISA
294 positive samples of *R. leschenaultia* failed to show any NAb, indicating the probability of cross
295 reacting antibodies against non-neutralizing epitopes²⁶. Antibody positivity by ELISA and Western
296 Blot in *R. leschenaultia* has been reported from China, but neutralization studies were not performed
297 in the samples²⁷.

298 The findings from the current outbreak, suggest that spill-over of NiV infection in humans is sporadic
299 and the seroprevalence in bats indicates the prevalence of the NiV infections in the *P. medius*

population. Stringent surveillance measures and awareness campaigns to limit interactions with bats needs to be implemented in the area as the NiV transmission dynamics depends on multiple host factors including human behavior and human-bat interface. For early detection and containment of NiV outbreaks, it is critical to strengthen human surveillance for Acute Encephalitis Syndrome and Severe Acute Respiratory Infection, including testing for NiV in susceptible areas.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Funding

ICMR supported the funding for this study under the mission-oriented project to the ICMR-National Institute of Virology, Pune. The funders had no role in study design, data collection or interpretation, or the decision to submit the work for publication. The findings and conclusions in this study are of the authors.

Acknowledgments

Authors extend gratitude to Veena George [Hon'ble Minister for Health and Social Justice, Kerala], for her exemplary leadership and efficient coordination of the Nipah virus disease control activities, and "The Team Kerala Health," the district administration, press, media, and people for their efforts in streamlining the public health responses. The authors are thankful to Prof. Balram Bhargava, Director General, ICMR and Dr Samiran Panda, Scientist G & Head, Epidemiology and Communicable Diseases Division, ICMR for their support. Authors are also thankful for the staff of the Administration section, ICMR-NIV Pune for their support during the outbreak response. We also

acknowledge the help and support received from Dr. Arun Sacharia, Chief Veterinarian (Wild life) and Dr. Arun Sathyan, Assistant Veterinarian, Thamaraserry during bat survey.

References

1. Chua KB, Goh KJ, Wong KT, et al. Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia. *Lancet* 1999;354(9186):1257–9.
2. Gurley ES, Spiropoulou CF, de Wit E. Twenty Years of Nipah Virus Research: Where Do We Go From Here? *The Journal of Infectious Diseases* 2020;221(Supplement_4):S359–62.
3. Paton NI, Leo YS, Zaki SR, et al. Outbreak of Nipah-virus infection among abattoir workers in Singapore. *Lancet* 1999;354(9186):1253–6.
4. Rahman M, Chakraborty A. Nipah virus outbreaks in Bangladesh: a deadly infectious disease. *WHO South East Asia J Public Health* 2012;1(2):208–12.
5. Chadha MS, Comer JA, Lowe L, et al. Nipah virus-associated encephalitis outbreak, Siliguri, India. *Emerg Infect Dis* 2006;12(2):235–40.
6. Arankalle VA, Bandyopadhyay BT, Ramdasi AY, et al. Genomic Characterization of Nipah Virus, West Bengal, India. *Emerg Infect Dis* 2011;17(5):907–9.
7. Yadav PD, Raut CG, Shete AM, et al. Detection of Nipah Virus RNA in Fruit Bat (*Pteropus giganteus*) from India. *Am J Trop Med Hyg* 2012;87(3):576–8.
8. Yadav P, Sudeep A, Gokhale M, et al. Circulation of Nipah virus in *Pteropus giganteus* bats in northeast region of India, 2015. *Indian J Med Res* 2018;147(3):318–20.

- 340 9. Arunkumar G, Chandni R, Mourya DT, et al. Outbreak Investigation of Nipah Virus Disease in
341 Kerala, India, 2018. *J Infect Dis* 2019; 219(12):1867–78.
- 342 10. Sahay RR, Yadav PD, Gupta N, Shete AM, Radhakrishnan C, Mohan G, et al. Experiential
343 learnings from the Nipah virus outbreaks in Kerala towards containment of infectious public
344 health emergencies in India. *Epidemiol Infect.* 2020; 148.
- 345 11. Sudeep AB, Yadav PD, Gokhale MD, Balasubramanian R, Gupta N, Shete A, et al. Detection of
346 Nipah virus in *P. medius* in 2019 outbreak from Ernakulam district, Kerala, India. *BMC Infect*
347 *Dis.* 2021; 21(1):1-7.
- 348 12. Linacre A, Lee JC. Species determination: the role and use of the cytochrome b gene. In *Forensic*
349 *DNA Typing Protocols* 2016 (pp. 287-296). Humana Press, New York,
- 350 13. NY.Guillaume V, Lefeuvre A, Faure C, Marianneau P, Buckland R, Lam SK et al. Specific
351 detection of Nipah virus using real-time RT-PCR (TaqMan). *Journal of virological methods.*
352 2004;120(2):229-37.
- 353 14. Choudhary ML, Vipat V, Jadhav S, Basu A, Cherian S, Abraham P, Potdar VA. Development of
354 in vitro transcribed RNA as positive control for laboratory diagnosis of SARS-CoV-2 in India.
355 *Indian J Med Res.* 2020;151(2-3):251.
- 356 15. Yadav PD, Whitmer SLM, Sarkale P, Fei Fan Ng T, Goldsmith CS, Nyayanit DA, et al.
357 Characterization of Novel Reoviruses Wad Medani Virus (Orbivirus) and Kundal Virus
358 (Coltivirus) Collected from Hyalomma anatolicum Ticks in India during Surveillance for
359 Crimean Congo Hemorrhagic Fever. *J Virol.* 2019; 93(13).

- 360 16. Gupta N, Kaur H, Yadav PD, Mukhopadhyay L, Sahay RR, Kumar A et al. Clinical
361 characterization and genomic analysis of samples from COVID-19 breakthrough infections
362 during the second wave among the various states of India. *Viruses*. 2021;13(9):1782.
- 363 17. Gokhale MD, Sreelekshmy M, Sudeep AB, Shete A, Jain R, Yadav PD, Mathapati B, Mourya
364 DT. Detection of possible Nipah virus infection in *Rousettus leschenaultii* and *Pipistrellus*
365 *Pipistrellus* bats in Maharashtra, India. *J Infect Public Health*. 2021;14(8):1010-2.
- 366 18. Epstein JH, Anthony SJ, Islam A, Kilpatrick AM, Khan SA, Balkey MD, et al. Nipah virus
367 dynamics in bats and implications for spillover to humans. *Proc. Natl. Acad. Sci. U.S.A.*
368 2020;117(46):29190-201.
- 369 19. Saikia U. A review of chiropterological studies and a distributional list of the bat fauna of India.
370 *Records of the Zoological Survey of India*. 2018;118(3):242-80.
- 371 20. Epstein JH, Prakash V, Smith CS, Daszak P, McLaughlin AB, Meehan G, et al. Henipavirus
372 infection in fruit bats (*Pteropus giganteus*), India. *Emerg Infect Dis*. 2008;14(8):1309.
- 373 21. Li K, Yan S, Wang N, He W, Guan H, He C, et al. Emergence and adaptive evolution of Nipah
374 virus. *Transbound Emerg Dis*. 2020;67(1):121-32.
- 375 22. Whitmer SL, Lo MK, Sazzad HM, Zufan S, Gurley ES, Sultana S, Amman B, Ladner JT,
376 Rahman MZ, Doan S, Satter SM. Inference of Nipah virus evolution, 1999–2015. *Virus Evol*.
377 2021;7(1):veaa062.
- 378 23. Yob JM, Field H, Rashdi AM, Morrissy C, van der Heide B, Rota P, et al. Nipah virus infection
379 in bats (order Chiroptera) in peninsular Malaysia. *Emerg Infect Dis*. 2001;7(3):439.

380 24. Epstein JH, Anthony SJ, Islam A, Kilpatrick AM, Khan SA, Ross N, et al. Nipah virus ecology
381 and infection dynamics in its bat reservoir, *Pteropus medius*, in Bangladesh. *Int J Infect Dis*.
382 2016; 53:20-1.

383 25. Wacharapluesadee S, Boongird K, Wanghongsa S, Ratanasetyuth N, Supavonwong P, Saengsen
384 D, et al. A longitudinal study of the prevalence of Nipah virus in *Pteropus lylei* bats in Thailand:
385 evidence for seasonal preference in disease transmission. *Vector Borne Zoonotic Dis*.
386 2010;10(2):183-90.

387 26. Hasebe F, Thuy NT, Inoue S, Yu F, Kaku Y, Watanabe S, Akashi H, Dat DT, Mai LT, Morita K.
388 Serologic evidence of nipah virus infection in bats, Vietnam. *Emerg Infect Dis*. 2012;18(3):536.

389 27. Li Y, Wang J, Hickey AC, Zhang Y, Li Y, Wu Y, Zhang H, Yuan J, Han Z, McEachern J, Broder
390 CC. Antibodies to Nipah or Nipah-like viruses in bats, China. *Emerg Infect Dis*.
391 2008;14(12):1974.

392

393

394

395 **Table 1: PNS for the representative NiV strains retrieved from GenBank database relative to NC_002728.1_NiV/MY/HU/1999/CDC**

NiV strains	PNS	NiV strains	PNS
NiV/India/HU/2021/sample	91.3	MK673560.1_NiV/MY/Pig/1999/808585	100
MN549409.1_NiV/India/P.medius/2019/MCL-19-BAT-572-7	91.5	MK673559.1_NiV/MY/Pig/1999/808581	100
MK801755.1_NiV/Cambodia/P.lylei/2003/CSUR381	97.7	MK673558.1_NiV/MY/Pig/1999/808579	100
MK673592.1_NiV/BD/HU/2014/201601241	91.6	MK575070.1_NiV/BD/P.medius/EHA/2013/Sylhet191	91.6
MK673591.1_NiV/BD/HU/2014/201601231	91.6	MK575069.1_NiV/BD/P.medius/EHA/2013/Raypur1411	91.6
MK673590.1_NiV/BD/HU/2014/201601191	91.6	MK575068.1_NiV/BD/P.medius/EHA/2013/Raypur1410	91.6
MK673589.1_NiV/BD/HU/2014/201601187	91.7	MK575067.1_NiV/BD/P.medius/EHA/2013/Raypur1409	91.6
MK673587.1_NiV/BD/HU/2015/201601144	91.5	MK575066.1_NiV/BD/P.medius/EHA/2013/Raypur1408	91.6
MK673586.1_NiV/BD/HU/2015/201601138	91.6	MK575065.1_NiV/BD/P.medius/EHA/2013/Raypur1406	91.6
MK673585.1_NiV/BD/HU/2015/201601136	91.6	MK575064.1_NiV/BD/P.medius/EHA/2013/Raypur1405	91.6
MK673584.1_NiV/BD/HU/2015/201601126	91.6	MK575063.1_NiV/BD/P.medius/EHA/2013/Raypur1404	91.8
MK673583.1_NiV/BD/HU/2013/201302591	91.6	MK575062.1_NiV/BD/P.medius/EHA/2013/Raypur1403	91.6
MK673582.1_NiV/BD/HU/2012/201206325	91.7	MK575061.1_NiV/BD/P.medius/EHA/2013/Raypur1402	91.6
MK673581.1_NiV/BD/HU/2012/201206316	91.7	MK575060.1_NiV/BD/P.medius/EHA/2013/Raypur1401	91.6
MK673579.1_NiV/BD/HU/2012/201206312	91.7	MH523642.1_NiV/India/HU/2018/MCL-18-H-1088	91.5
MK673578.1_NiV/BD/HU/2011/201206119	91.7	MH523641.1_NiV/India/HU/2018/MCL-18-H-1209	91.5

MK673577.1_NiV/BD/HU/2011/201206008	91.7	MH523640.1_NiV/India/HU/2018/MCL-18-H-1197	91.6
MK673576.1_NiV/BD/HU/2011/201200973	91.6	MH396625.1_NiV/India/HU/2018/MCL-18-H-1088	91.5
MK673575.1_NiV/BD/HU/2011/201200938	91.6	JN808863.1_NiV/BD/HU/2008/RAJBARI	91.7
MK673574.1_NiV/BD/HU/2011/201200920	91.7	JN808857.1_NiV/BD/HU/2008/MANIKGONJ	91.7
MK673573.1_NiV/BD/HU/2011/201200919	91.7	FJ513078.1_NiV/India/HU/2007/FG	91.6
MK673571.1_NiV/BD/HU/2011/201200903	91.7	AY988601.1_NiV/Bangladesh/HU/2004/RA1	91.8
MK673570.1_NiV/BD/HU/2011/812001	91.6	AY029768.1_NiV/MY/HU/1999/UMMC2	100
MK673568.1_NiV/BD/HU/2008/811373	91.8	AY029767.1_NiV/MY/HU/1999/UMMC1	100
MK673567.1_NiV/BD/HU/2004/810482	91.7	AJ627196.1_NiV/MY/Pig/99/VRI-0626	99.7
MK673566.1_NiV/BD/HU/2004/810428	91.7	AJ564623.1_NiV/MY/Pig/1999/UM-0128	100
MK673565.1_NiV/BD/HU/2012/810405	91.8	AJ564622.1_NiV/MY/Pig/1999/VRI-1413	100
MK673564.1_NiV/BD/HU/2004/810398	91.8	AJ564621.1_NiV/MY/Pig/1999/VRI-2794	100
MK673563.1_NiV/MY/Dog/1999/808652	100	AF376747.1_NiV/MY/Pig/1999/VRI-0626	99.9
MK673562.1_NiV/MY/HU/1999/808651	99.9	AF212302.2_Nipah_virus	100
MK673561.1_NiV/MY/Pig/1999/808589	100		

Table.2: Amino acid changes in the different genotype across representative human and bat sequences for genes encoded by NiV relative to NC 002728.1

Nipah virus strain	Geno type	Species	N gene																										
			5	5	5	5	5	6	7	7	7	8	8	8	8	8	8	8	8	9	9	9	9	9	9	9	1	1	121
			0	0	2	9	9	1	5	5	6	1	2	3	3	3	4	4	4	0	1	2	5	5	8	6	8		
			3	5	0	4	7	4	2	8	1	8	0	0	1	3	3	4	5	0	9	1	4	8	2	2	8		
NC 002728.1 NiV/MY/HU/1999/CDC	M	Human	S	R	P	G	S	T	E	Q	R	R	I	Q	A	D	G	P	K	S	T	D	P	S	Q	A	M	G	
NiV/India/HU/2021/sample	I	Human	N	.	S	.	.	.	G	E	.	H	L	.	I	G	.	L	.	.	N	.	L	.	R	T	.	D	
MH523642.1 NiV/India/HU/2018/MCL-18-H-1088	I	Human	N	.	S	.	.	.	G	E	.	H	L	K	I	G	.	L	.	.	N	.	L	N	R	T	.	D	
MN549409.1 NiV/India/P.medi	I	Bat	N	.	S	.	.	.	G	E	.	H	L	.	I	G	.	L	.	.	N	.	.	.	R	T	.	D	

[illegible]

MN549409.1 NiV/India/P.medi us/2019/MCL- 19-BAT-572-7	I	Bat	L	.	M	V	.	I	.	T	.	.	.	.	Y	.	.	.	.
MK673592.1 NiV/BD/HU/201 4/201601241	B	Human	.	I	K	.	E	.	K	.	.	.	.	.	Y	Y	.	K	D
MK575070.1 NiV/BD/P.medi us/EHA/2013/Sylh et191	B	Bat	.	.	K	.	E	.	K	T	R	S	M	D	.	Y	I	K	D

Table. 3: Results and real time RT-PCR, anti-Nipah IgG ELISA and PRNT in bat samples

*2 samples excluded from PRNT assay excluded due to insufficient sample volume

	Bat species	Location of capture	Real time RT-PCR positivity/total tested	Anti-Nipah IgG positivity by ELISA/total tested (%)	Anti-Nipah IgG positivity by PRNT/total tested
1	<i>Pteropus medius</i>	Kodiyathur	0/16	3/15 (20)	3/3
		Cheruvadi	0/2	0/2 (0)	0/0
		Omassery	0/12	0/12 (0)	0/0
		Thamarassery	0/9	5/9 (55.6)*	3/3
2	<i>Rousettus leschenaultii</i>	Kodiyathur	0/5	1/4 (25)	0/1
		Cheruvadi	0/43	19/38 (50)	0/17
		Omassery	0/12	0/10	0/0
		Thamarassery	0/3	0/1	0/0
3	<i>Pipistrellus sp.</i>	Cheruvadi	0/1	0/0	0/0

Figure 1: Contact tracing and probable transmission dynamics in the Nipah virus outbreak in Kozhikode district, Kerala state, India, 2021

410

411 **Figure 2:** Neighbor Joining tree of Nipah virus full genome obtained from the samples of index case
412 in Kerala outbreak 2021